Salama H, Zekri ARN, Bahnassy AA, Medhat E, Halim HA, Ahmed OS, Mohamed G, Alim SAA, Sherif GM. Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease. World J Gastroenterol 2010; 16(42): 5297-5305 [PMID: 21072892 DOI: 10.3748/wjg.v16.i42.5297]
Corresponding Author of This Article
Abdel-Rahman N Zekri, Professor, Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Kasr Al-Aini st., Fom El-Khaleeg, 11976 Cairo, Egypt. ncizekri@yahoo.com
Article-Type of This Article
Original Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Salama H, Zekri ARN, Bahnassy AA, Medhat E, Halim HA, Ahmed OS, Mohamed G, Alim SAA, Sherif GM. Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease. World J Gastroenterol 2010; 16(42): 5297-5305 [PMID: 21072892 DOI: 10.3748/wjg.v16.i42.5297]
World J Gastroenterol. Nov 14, 2010; 16(42): 5297-5305 Published online Nov 14, 2010. doi: 10.3748/wjg.v16.i42.5297
Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease
Hosny Salama, Abdel-Rahman N Zekri, Abeer A Bahnassy, Eman Medhat, Hanan A Halim, Ola S Ahmed, Ghada Mohamed, Sheren A Al Alim, Ghada M Sherif
Hosny Salama, Eman Medhat, Hanan A Halim, Ghada Mohamed, Sheren A Al Alim, Tropical Medicine Department, El-Kasr Al-Aini School of Medicine, Kasr Al-Aini st., Kasr Al-Aini, 11977 Cairo, Egypt
Abdel-Rahman N Zekri, Ola S Ahmed, Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Kasr Al-Aini st., Fom El-Khaleeg, 11976 Cairo, Egypt
Abeer A Bahnassy, Pathology Department, National Cancer Institute, Cairo University, Kasr Al-Aini st., Fom El-Khaleg, 11976 Cairo, Egypt
Ghada M Sherif, Biostatistics and Epidemiology Department, National Cancer Institute, Cairo University, 11976 Cairo, Egypt
Author contributions: Salama H and Zekri ARN contributed equally to this work and also designed the research; Salama H, Zekri ARN, Bahnassy AA, Medhat E, Halim HA, Ahmed OS, Mohamed G and Al Alim SA performed the research and contributed new reagents/analytic tools; Sherif GM analyzed the data; Salama H, Zekri ARN and Bahnassy AA wrote the paper.
Supported by Grand Office of Cairo University
Correspondence to: Abdel-Rahman N Zekri, Professor, Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Kasr Al-Aini st., Fom El-Khaleeg, 11976 Cairo, Egypt. ncizekri@yahoo.com
Telephone: +20-2-22742607 Fax: +20-2-23644720
Received: June 3, 2010 Revised: July 6, 2010 Accepted: July 13, 2010 Published online: November 14, 2010
Abstract
AIM: To assess the utility of an autologous CD34+ and CD133+ stem cells infusion as a possible therapeutic modality in patients with end-stage liver diseases.
METHODS: One hundred and forty patients with end-stage liver diseases were randomized into two groups. Group 1, comprising 90 patients, received granulocyte colony stimulating factor for five days followed by autologous CD34+ and CD133+ stem cell infusion in the portal vein. Group 2, comprising 50 patients, received regular liver treatment only and served as a control group.
RESULTS: Near normalization of liver enzymes and improvement in synthetic function were observed in 54.5% of the group 1 patients; 13.6% of the patients showed stable states in the infused group. None of the patients in the control group showed improvement. No adverse effects were noted.
CONCLUSION: Our data showed that a CD34+ and CD133+ stem cells infusion can be used as supportive treatment for end-stage liver disease with satisfactory tolerability.
